ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

Associations of HLA-DRB1 Haplotypes with Disease Characteristics and All-Cause Mortality in Rheumatoid Arthritis

Lilli Mauer1, Ted R Mikuls2, Bryant R. England1, Grant W. Cannon3, Gail S. Kerr4, Geoffrey M. Thiele5, Liron Caplan6, Michael J. Duryee7 and Andreas M. Reimold8, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, 4Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, 5University of Nebraska Medical Center, Omaha, NE, 6Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, 7Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 8Rheumatology, VAMC and University of Texas Southwestern, Dallas, TX

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Genetic Biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose : Numerous genetic susceptibility loci have been identified in RA. The HLA-DRB1 shared epitope (SE) sequence is most strongly associated, though there has been increasing interest in amino acids outside the SE region. Recently, investigators have identified 16 HLA haplotypes defined by amino acids at positions 11, 71, and 74. Valine at position 11, particularly the VKA haplotype, has been associated with radiographic progression, mortality, and poor RA treatment response. In this study we examined HLA haplotypes and associations with mortality, presence of subcutaneous nodules, radiographic damage, and RA-associated autoantibodies.

Methods: The study included 1443 U.S veteran participants. Clinical characteristics were recorded at enrolment. Mortality was ascertained via linkage to the National Death Index. DNA was obtained at enrollment and 4-digit HLA-DRB1 genotyping was completed. Amino acids at positions 11, 71, and 74 were determined, and haplotypes assigned based on three amino acid combinations. RF and aCCP were measured from banked serum. Haplotype associations with mortality were examined using age- and sex-adjusted Cox proportional hazards regression, while associations with other disease characteristics were examined using Chi square or Student’s t-tests comparing subjects with at least one copy of a given haplotype to those with no copies.

Results: The most frequent haplotype was VKA with 34% of subjects possessing at least one copy. Eight haplotypes were present in frequencies >10% (VKA, VRA, LRA, PAA, GRQ, SRA, SKR, SEA). We found an increased risk of all-cause mortality with SKA (HR 1.38 [95% CI 1.13-1.69]) but not with SE status or other haplotypes, including those with valine at position 11. Radiographic damage was more common in patients with VKA (60% vs 51%, p = 0.002) or VRE (70% vs 53%, p = 0.032) but less common with SRA (44% vs 55%, p = 0.005) and SEA (46% vs 57%, p = 0.023). There were no haplotype associations with subcutaneous nodules. We identified associations between several haplotypes and autoantibody concentration (Table). The VKA haplotype was associated with higher RF and aCCP concentrations. SE positivity based on dual autoantibody status was: RF+/aCCP+ = 77%; RF-/aCCP+ = 79%; RF+/aCCP- = 53%; and RF-/aCCP- = 56%. A similar pattern was observed for VKA haplotype positivity: RF+/aCCP+ = 39%; RF-/aCCP+ = 37%; RF+/aCCP- = 18%; and RF-/aCCP- = 18%.

Conclusion: In contrast to recent reports, we observed little association between HLA haplotype and all cause mortality. However, there were associations of both VKA and VRE haplotypes with presence of radiographic damage and robust associations of VKA with higher RF and aCCP values. Our observations also suggest that associations of both SE and VKA status with seropositivity are driven by associations with aCCP status independent of RF.      

RF and aCCP concentrations based on HLA-DRB1 haplotype

Rheumatoid Factor Concentration (IU/ml; mean ± SD)

Anti-CCP Concentration (U/ml; mean ± SD)

Haplotype

Haplotype+

Haplotype-

P

Haplotype+

Haplotype-

P

VKA

347 (639)

321 (676)

<0.001

331 (510)

243 (407)

<0.001

VRA

317 (520)

334 (709)

0.048

303 (449)

261 (445)

0.162

LRA

356 (766)

321 (623)

0.964

311 (485)

259 (431)

0.271

PRA

231 (579)

333 (665)

0.471

291 (295)

272 (450)

0.137

VRE

242 (341)

333 (672)

0.968

267 (488)

273 (445)

0.161

DRE

294 (401)

331 (672)

0.046

156 (218)

278 (453)

0.233

VEA

298 (635)

330 (664)

0.502

138 (164)

274 (448)

0.390

SKA

293 (522)

331 (668)

0.969

258 (304)

273 (451)

0.111

PAA

359 (734)

322 (645)

0.655

323 (478)

260 (438)

0.235

GRQ

218 (371)

352 (705)

0.018

275 (502)

272 (435)

0.561

SRA

359 (649)

325 (666)

0.450

244 (431)

277 (449)

0.854

SRE

415 (968)

327 (653)

0.411

211 (398)

275 (448)

0.304

LEA

170 (282)

332 (667)

0.092

126 (167)

275 (449)

0.466

SRL

315 (518)

330 (669)

0.495

258 (397)

273 (449)

0.826

SKR

342 (796)

327 (635)

0.046

155 (336)

296 (461)

<0.001

SEA

309 (607)

334 (673)

0.086

191 (360)

287 (459)

0.001

*P-values generated from t-test comparing log-transformed values


Disclosure: L. Mauer, None; T. R. Mikuls, None; B. R. England, None; G. W. Cannon, Amgen, 2; G. S. Kerr, UCB, Janssen, 9; G. M. Thiele, None; L. Caplan, None; M. J. Duryee, None; A. M. Reimold, Abbvie, 2,Novartis Pharmaceutical Corporation, 2.

To cite this abstract in AMA style:

Mauer L, Mikuls TR, England BR, Cannon GW, Kerr GS, Thiele GM, Caplan L, Duryee MJ, Reimold AM. Associations of HLA-DRB1 Haplotypes with Disease Characteristics and All-Cause Mortality in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/associations-of-hla-drb1-haplotypes-with-disease-characteristics-and-all-cause-mortality-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-hla-drb1-haplotypes-with-disease-characteristics-and-all-cause-mortality-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology